Literature DB >> 22980036

Prognostic scoring systems in MDS.

Ulrich Germing1, Andrea Kündgen.   

Abstract

Prognostic scoring systems in myelodysplastic syndromes are useful tools in order to get in idea on the expected course of the disease and offer patients a risk adapted treatment. Several good scores have been developed, the international prognostic scoring system (IPSS) being the gold standard for 15 years, now validated and refined. As more and more patients receive therapy and drugs are approved, the major goal for future projects must be the identification of predictive parameters and scoring systems in order to predict the response and outcome after specific treatments.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22980036     DOI: 10.1016/j.leukres.2012.08.005

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  Does a diagnosis of myelogenous leukemia require 20% marrow myeloblasts, and does <5% marrow myeloblasts represent a remission? The history and ambiguity of arbitrary diagnostic boundaries in the understanding of myelodysplasia.

Authors:  Marshall A Lichtman
Journal:  Oncologist       Date:  2013-08-27

2.  A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy.

Authors:  D Sanford; C C Hsia
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

Review 3.  Myelodysplastic syndromes: diagnosis, prognosis, and treatment.

Authors:  Ulrich Germing; Guido Kobbe; Rainer Haas; Norbert Gattermann
Journal:  Dtsch Arztebl Int       Date:  2013-11-15       Impact factor: 5.594

Review 4.  There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.

Authors:  Amer M Zeidan; Rami S Komrokji
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 5.  Acquired myelodysplasia or myelodysplastic syndrome: clearing the fog.

Authors:  Ethan A Natelson; David Pyatt
Journal:  Adv Hematol       Date:  2013-10-07

6.  Improved intra-array and interarray normalization of peptide microarray phosphorylation for phosphorylome and kinome profiling by rational selection of relevant spots.

Authors:  Jetse Scholma; Gwenny M Fuhler; Jos Joore; Marc Hulsman; Stefano Schivo; Alan F List; Marcel J T Reinders; Maikel P Peppelenbosch; Janine N Post
Journal:  Sci Rep       Date:  2016-05-26       Impact factor: 4.379

7.  Clinical Prognostic Factors in 86 Chinese Patients with Primary Myelodysplastic Syndromes and Trisomy 8: A Single Institution Experience.

Authors:  Qing Fang Yue; Lei Chen; Xiao Mei She; Bin Hu; Yu Hu; Ping Zou; Xin Yue Liu
Journal:  Yonsei Med J       Date:  2016-03       Impact factor: 2.759

8.  Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS.

Authors:  Christina Rautenberg; Ulrich Germing; Sabrina Pechtel; Marius Lamers; Carolin Fischermanns; Paul Jäger; Stefanie Geyh; Rainer Haas; Guido Kobbe; Thomas Schroeder
Journal:  Blood Cancer J       Date:  2019-11-12       Impact factor: 11.037

9.  Evaluation of different scoring systems and gene mutations for the prognosis of myelodysplastic syndrome (MDS) in Chinese population.

Authors:  Meng-Yi Du; Min Xu; Jun Deng; Lin Liu; Tao Guo; Ling-Hui Xia; Yu Hu; Heng Mei
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.